1. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003; 48:257–293.
Article
2. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013; 27:787–794.
3. Wickham L, Konstantinidis L, Wolfensberger TJ, et al. Epiretinal membranes, vitreoretinal traction, and cystoid macular edema. In : Schachat AP, editor. Ryan's Retina. 6th ed. Philadelphia: Elsevier Inc.;2017. 3:chap. 120.
4. Chen YS, Hackett SF, Schoenfeld CL, et al. Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br J Ophthalmol. 1997; 81:919–926.
Article
5. Abouammoh MA, Belliveau MJ, Almeida DR, et al. Ranibizumab for idiopathic epiretinal membranes: a retrospective case series. Saudi J Ophthalmol. 2013; 27:79–82.
Article
6. Marticorena J, Romano MR, Heimann H, et al. Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect? Br J Ophthalmol. 2011; 95:391–395.
Article
7. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One. 2008; 3:e2675.
Article
8. Zhang Q, Qi Y, Chen L, et al. The relationship between anti-vascular endothelial growth factor and fibrosis in proliferative retinopathy: clinical and laboratory evidence. Br J Ophthalmol. 2016; 100:1443–1450.
Article
9. Chu SJ, Zhang ZH, Wang M, Xu HF. Effect of bevacizumab on the expression of fibrosis-related inflammatory mediators in ARPE-19 cells. Int J Ophthalmol. 2017; 10:366–371.
Article
10. Zhang JJ, Chu SJ, Sun XL, et al. Bevacizumab modulates retinal pigment epithelial-to-mesenchymal transition via regulating Notch signaling. Int J Ophthalmol. 2015; 8:245–249.